Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- New Dosage Strength Approved for Enbrel Pen: Pfizer
February 14, 2018
- Adcetris Filed in Japan for Frontline Hodgkin’s Lymphoma: Takeda
February 14, 2018
- Zytiga Shows Consistent Efficacy in Japanese High-Risk mHNPC Patients
February 14, 2018
- New IITs for Oncolytic Virus to Begin for Head and Neck Cancer, Sarcoma: Oncolys
February 13, 2018
- Pricing Revamp for Off-Patent Brands “Within Our Expectation”: LTL Pharma CEO
February 13, 2018
- 2018 to See Transition to “Leap Phase” in Kyowa Kirin’s Midterm Plan: President
February 13, 2018
- Hiroshima Couple Arrested for Counterfeit Harvoni Case
February 9, 2018
- Nipro Grabs Rights to TC BioPharm’s CAR-T Therapy
February 9, 2018
- Kyowa Kirin Logs Higher Earnings on Milestones, Lower R&D Costs
February 9, 2018
- Ethical Drug Sales Up 2.1% in December on Cancer Meds, SGLT2
February 9, 2018
- Hisamitsu to Form Hong Kong Subsidiary to Step Up Salonpas, Mohrus Sales
February 9, 2018
- Otsuka Ups 2017 Profit Estimate on US Tax Reform
February 9, 2018
- Positive RA Data Out for JAK Inhibitor Peficitinib, Astellas Gears Up for Filing
February 9, 2018
- Fujifilm, Takeda Strike Deal on iPS Cell-Based Heart Therapy
February 9, 2018
- YL Biologics’ Enbrel Biosimilar Shows Equivalent Efficacy to Originator
February 8, 2018
- Daiichi Sankyo’s ADC U3-1402 Enters PI Study in US for NSCLC, Eyeing Its Multinational Study
February 8, 2018
- Torii Enjoys Earnings Rise on New HIV Drugs
February 7, 2018
- Xtandi Cuts Risk of Metastasis or Deaths by 71% in Non-Metastatic CRPC
February 7, 2018
- EA Pharma Launches Rectabul, Boosts Efforts on Humira to Gird for IBD Showdown
February 7, 2018
- Poxel Eyeing Japan as 1st Market for Its Lead Diabetes Candidate: CEO
February 6, 2018
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…